交易 ACADIA Pharmaceuticals Inc - ACAD 差價合約
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson''s disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.最新股票文章
期貨是什麼？一文看懂期貨合約運作、種類與香港交易入門
期貨是什麼？本文拆解期貨合約組成、保證金計算與常見類型（股指、商品、加密貨幣），並詳解香港恒指期貨玩法、開戶流程及風險管理，新手必讀入門教學。
10:57, 16 6月 2026
ETF是什麼？一文讀懂交易所買賣基金的運作、種類與投資方法
ETF是什麼？本文深入解析交易所買賣基金的運作原理、主要類型（指數、債券、主題、槓桿反向）、投資費用及香港/美股熱門ETF清單，幫助新手快速開始ETF投資。
10:21, 16 6月 2026
港人實戰：如何佈局 SpaceX IPO 前後的交易節奏
SpaceX以750億美元完成歷史性IPO，估值1.77萬億美元。深度解析港股CFD交易策略、供應鏈映射與恒生指數聯動，助投資者理解太空經濟相關市場動態。資本面臨風險。
08:58, 16 6月 2026
SpaceX上市首日收漲19%——IPO後如何交易SpaceX SPCX差價合約
SpaceX（SPCX）於2026年6月12日在納斯達克首次上市，開盤報150美元，收盤報160.95美元，較135美元的IPO發行價上漲19.2%。
08:23, 16 6月 2026
評級和評論
評級和評論
